Company intelligence / Profile preview

TetraGenetics

Cambridge, Massachusetts, United States

Ownership: Private
Employees: ~11
Development stage: Other

Overview

TetraGenetics has developed a proprietary platform enabling the high-yield production of functional, complex recombinant transmembrane proteins such as ion channels and GPCRs for antibody discovery against difficult-to-drug targets. Its work underpins drug discovery for autoimmune diseases and pain but has not advanced to clinical-stage programs itself

Therapeutic areas: ImmunologyNeurologyOther
Modalities: Recombinant proteinAntibody
Industry: Drug Discovery Services

Partnerships

AbCellera (parent company)Partnerships with pharmaceutical/biotech companies using the platform for antibody discovery (historically, e.g., Heptares Therapeutics for GPCR projects)

Beyond the preview

Go deeper on TetraGenetics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TetraGenetics.

Explore the full profile